Work at Shanghai Institute of Organic Chemistry has led to the identification of new receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors. They are described as potentially useful for the treatment of ischemia-reperfusion injury, Parkinson’s disease, autoimmune diseases, glaucoma, traumatic brain injury, inflammatory disorders, bacterial infections and lysosomal storage diseases, among others.